

Jeremy N Rich

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1362934/jeremy-n-rich-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

264
papers

33,655
citations

90
h-index

181
g-index

283
ext. papers

39,428
ext. citations

13
avg, IF

7.14
L-index

#	Paper	IF	Citations
264	Glioblastoma stem cells reprogram chromatin in vivo to generate selective therapeutic dependencies on DPY30 and phosphodiesterases.. <i>Science Translational Medicine</i> , 2022 , 14, eabf3917	17.5	0
263	USP33 deubiquitinates and stabilizes HIF-2alpha to promote hypoxia response in glioma stem cells.. <i>EMBO Journal</i> , 2022 , e109187	13	2
262	A FBXO7/EYA2-SCF axis promotes AXL-mediated maintenance of mesenchymal and immune evasion phenotypes of cancer cells.. <i>Molecular Cell</i> , 2022 ,	17.6	2
261	CHMP2A regulates tumor sensitivity to natural killer cell-mediated cytotoxicity.. <i>Nature Communications</i> , 2022 , 13, 1899	17.4	0
260	Meningioma DNA methylation groups identify biological drivers and therapeutic vulnerabilities.. <i>Nature Genetics</i> , 2022 , 54, 649-659	36.3	0
259	EPEN-18. Oncogenic 3D genome conformations identify novel therapeutic targets in ependymoma. <i>Neuro-Oncology</i> , 2022 , 24, i42-i42	1	
258	Transcription Elongation Machinery Is a Druggable Dependency and Potentiates Immunotherapy in Glioblastoma Stem Cells. <i>Cancer Discovery</i> , 2021 ,	24.4	4
257	Targeting glioblastoma signaling and metabolism with a re-purposed brain-penetrant drug. <i>Cell Reports</i> , 2021 , 37, 109957	10.6	1
256	Targeting EYA2 tyrosine phosphatase activity in glioblastoma stem cells induces mitotic catastrophe. <i>Journal of Experimental Medicine</i> , 2021 , 218,	16.6	2
255	ETMM-08 METABOLIC REGULATION OF THE EPIGENOME DRIVES LETHAL INFANTILE EPENDYMOMA. <i>Neuro-Oncology Advances</i> , 2021 , 3, i15-i16	0.9	78
254	Phage display targeting identifies EYA1 as a regulator of glioblastoma stem cell maintenance and proliferation. <i>Stem Cells</i> , 2021 , 39, 853-865	5.8	3
253	PI3K inhibition suppresses microglia/TAM accumulation in glioblastoma microenvironment to promote exceptional temozolomide response. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021 , 118,	11.5	6
252	Brd4-bound enhancers drive cell-intrinsic sex differences in glioblastoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021 , 118,	11.5	6
251	Altered lipid metabolism marks glioblastoma stem and non-stem cells in separate tumor niches. <i>Acta Neuropathologica Communications</i> , 2021 , 9, 101	7.3	9
250	Epitranscriptomic editing of the RNA N6-methyladenosine modification by dCasRx conjugated methyltransferase and demethylase. <i>Nucleic Acids Research</i> , 2021 , 49, 7361-7374	20.1	15
249	A vaccine for glioma.. <i>Nature Cancer</i> , 2021 , 2, 584-586	15.4	1
248	Inhibiting DNA-PK induces glioma stem cell differentiation and sensitizes glioblastoma to radiation in mice. <i>Science Translational Medicine</i> , 2021 , 13,	17.5	7

247	A delicate initiation: Lipolysis of lipid droplets fuels glioblastoma. <i>Molecular Cell</i> , 2021 , 81, 2686-2687	17.6	1
246	The RNA m6A Reader YTHDF2 Maintains Oncogene Expression and Is a Targetable Dependency in Glioblastoma Stem Cells. <i>Cancer Discovery</i> , 2021 , 11, 480-499	24.4	73
245	Effect of a Multifactorial Fall Injury Prevention Intervention on Patient Well-Being: The STRIDE Study. <i>Journal of the American Geriatrics Society</i> , 2021 , 69, 173-179	5.6	3
244	CRISPR Screening of CAR T Cells and Cancer Stem Cells Reveals Critical Dependencies for Cell-Based Therapies. <i>Cancer Discovery</i> , 2021 , 11, 1192-1211	24.4	21
243	FBXO44 promotes DNA replication-coupled repetitive element silencing in cancer cells. <i>Cell</i> , 2021 , 184, 352-369.e23	56.2	15
242	Biomaterials and 3D Bioprinting Strategies to Model Glioblastoma and the Blood-Brain Barrier. <i>Advanced Materials</i> , 2021 , 33, e2004776	24	14
241	Plasma cells shape the mesenchymal identity of ovarian cancers through transfer of exosome-derived microRNAs. <i>Science Advances</i> , 2021 , 7,	14.3	5
240	Zika virus oncolytic activity requires CD8+ T cells and is boosted by immune checkpoint blockade. <i>JCI Insight</i> , 2021 , 6,	9.9	14
239	Leveraging Allele-Specific Expression for Therapeutic Response Gene Discovery in Glioblastoma.. <i>Cancer Research</i> , 2021 ,	10.1	2
238	Adipocytes promote breast tumorigenesis through TAZ-dependent secretion of Resistin. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020 , 117, 33295-33304	11.5	14
237	Reprogramming the microenvironment: tricks of tumor-derived astrocytes. <i>Cell Research</i> , 2020 , 30, 633-644	11.7	1
236	Dual Role of WISP1 in maintaining glioma stem cells and tumor-supportive macrophages in glioblastoma. <i>Nature Communications</i> , 2020 , 11, 3015	17.4	34
235	Three-dimensional bioprinted glioblastoma microenvironments model cellular dependencies and immune interactions. <i>Cell Research</i> , 2020 , 30, 833-853	24.7	63
234	A Randomized Trial of a Multifactorial Strategy to Prevent Serious Fall Injuries. <i>New England Journal of Medicine</i> , 2020 , 383, 129-140	59.2	51
233	Protein sumoylation with SUMO1 promoted by Pin1 in glioma stem cells augments glioblastoma malignancy. <i>Neuro-Oncology</i> , 2020 , 22, 1809-1821	1	6
232	Glioblastoma Stem Cells: Driving Resilience through Chaos. <i>Trends in Cancer</i> , 2020 , 6, 223-235	12.5	71
231	Zika Virus Targets Glioblastoma Stem Cells through a SOX2-Integrin α Axis. <i>Cell Stem Cell</i> , 2020 , 26, 187-204.e10	18	65
230	Type I Interferon Regulates a Coordinated Gene Network to Enhance Cytotoxic T Cell-Mediated Tumor Killing. <i>Cancer Discovery</i> , 2020 , 10, 382-393	24.4	10

229	SATB2 drives glioblastoma growth by recruiting CBP to promote FOXM1 expression in glioma stem cells. <i>EMBO Molecular Medicine</i> , 2020 , 12, e12291	12	12
228	Metabolic Regulation of the Epigenome Drives Lethal Infantile Ependymoma. <i>Cell</i> , 2020 , 181, 1329-1345.e24	56.2	40
227	The Meningioma Enhancer Landscape Delineates Novel Subgroups and Drives Druggable Dependencies. <i>Cancer Discovery</i> , 2020 , 10, 1722-1741	24.4	9
226	Glioma stem-like cells evade interferon suppression through MBD3/NuRD complex-mediated STAT1 downregulation. <i>Journal of Experimental Medicine</i> , 2020 , 217,	16.6	14
225	Zika virus is transmitted in neural progenitor cells via cell-to-cell spread and infection is inhibited by the autophagy inducer trehalose. <i>Journal of Virology</i> , 2020 ,	6.6	2
224	Targeting Glioblastoma Stem Cells through Disruption of the Circadian Clock. <i>Cancer Discovery</i> , 2019 , 9, 1556-1573	24.4	67
223	Mitochondrial NIX Promotes Tumor Survival in the Hypoxic Niche of Glioblastoma. <i>Cancer Research</i> , 2019 , 79, 5218-5232	10.1	36
222	The dystroglycan receptor maintains glioma stem cells in the vascular niche. <i>Acta Neuropathologica</i> , 2019 , 138, 1033-1052	14.3	12
221	SUFU: The Jekyll and Hyde of the Cerebellum. <i>Developmental Cell</i> , 2019 , 48, 131-132	10.2	0
220	Reply to Assembling the brain trust: the multidisciplinary imperative in neuro-oncology <i>Nature Reviews Clinical Oncology</i> , 2019 , 16, 522-523	19.4	
219	Glioblastoma stem cells: lessons from the tumor hierarchy in a lethal cancer. <i>Genes and Development</i> , 2019 , 33, 591-609	12.6	135
218	Glioma Stem Cell-Specific Superenhancer Promotes Polyunsaturated Fatty-Acid Synthesis to Support EGFR Signaling. <i>Cancer Discovery</i> , 2019 , 9, 1248-1267	24.4	60
217	Mechanism of Action of Methotrexate Against Zika Virus. <i>Viruses</i> , 2019 , 11,	6.2	21
216	Activity of Selected Nucleoside Analogue ProTides against Zika Virus in Human Neural Stem Cells. <i>Viruses</i> , 2019 , 11,	6.2	8
215	Single-Cell Transcriptomics Uncovers Glial Progenitor Diversity and Cell Fate Determinants during Development and Gliomagenesis. <i>Cell Stem Cell</i> , 2019 , 24, 707-723.e8	18	68
214	Chromatin landscapes reveal developmentally encoded transcriptional states that define human glioblastoma. <i>Journal of Experimental Medicine</i> , 2019 , 216, 1071-1090	16.6	44
213	Challenges to curing primary brain tumours. <i>Nature Reviews Clinical Oncology</i> , 2019 , 16, 509-520	19.4	284
212	Targeting pyrimidine synthesis accentuates molecular therapy response in glioblastoma stem cells. <i>Science Translational Medicine</i> , 2019 , 11,	17.5	46

211	A C19MC-LIN28A-MYCN Oncogenic Circuit Driven by Hijacked Super-enhancers Is a Distinct Therapeutic Vulnerability in ETMRs: A Lethal Brain Tumor. <i>Cancer Cell</i> , 2019 , 36, 51-67.e7	24.3	39
210	Oncogene Amplification in Growth Factor Signaling Pathways Renders Cancers Dependent on Membrane Lipid Remodeling. <i>Cell Metabolism</i> , 2019 , 30, 525-538.e8	24.6	65
209	Treatment of glioblastoma using multicomponent silica nanoparticles. <i>Advanced Therapeutics</i> , 2019 , 2, 1900118	4.9	11
208	Chromatin remodeler HELLS maintains glioma stem cells through E2F3 and MYC. <i>JCI Insight</i> , 2019 , 4,	9.9	21
207	Functional Enhancers Shape Extrachromosomal Oncogene Amplifications. <i>Cell</i> , 2019 , 179, 1330-1341.e136.2	36.2	87
206	Cancer Stem Cells: The Architects of the Tumor Ecosystem. <i>Cell Stem Cell</i> , 2019 , 24, 41-53	18	240
205	Poly(ADP-Ribose) Polymerase Inhibition Sensitizes Colorectal Cancer-Initiating Cells to Chemotherapy. <i>Stem Cells</i> , 2019 , 37, 42-53	5.8	13
204	Reciprocal Signaling between Glioblastoma Stem Cells and Differentiated Tumor Cells Promotes Malignant Progression. <i>Cell Stem Cell</i> , 2018 , 22, 514-528.e5	18	110
203	A posttranslational modification of the mitotic kinesin Eg5 that enhances its mechanochemical coupling and alters its mitotic function. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018 , 115, E1779-E1788	11.5	9
202	Therapeutic targeting of ependymoma as informed by oncogenic enhancer profiling. <i>Nature</i> , 2018 , 553, 101-105	50.4	116
201	AMPK/FIS1-Mediated Mitophagy Is Required for Self-Renewal of Human AML Stem Cells. <i>Cell Stem Cell</i> , 2018 , 23, 86-100.e6	18	116
200	Inhibition of ID1-BMP2 Intrinsic Signaling Sensitizes Glioma Stem Cells to Differentiation Therapy. <i>Clinical Cancer Research</i> , 2018 , 24, 383-394	12.9	16
199	N-methyladenine DNA Modification in Glioblastoma. <i>Cell</i> , 2018 , 175, 1228-1243.e20	56.2	153
198	Ibrutinib inactivates BMX-STAT3 in glioma stem cells to impair malignant growth and radioresistance. <i>Science Translational Medicine</i> , 2018 , 10,	17.5	62
197	Glioblastoma on a microfluidic chip: Generating pseudopalisades and enhancing aggressiveness through blood vessel obstruction events. <i>Neuro-Oncology</i> , 2017 , 19, 503-513	1	40
196	Messenger RNA Methylation Regulates Glioblastoma Tumorigenesis. <i>Cancer Cell</i> , 2017 , 31, 474-475	24.3	32
195	Tumour-associated macrophages secrete pleiotrophin to promote PTPRZ1 signalling in glioblastoma stem cells for tumour growth. <i>Nature Communications</i> , 2017 , 8, 15080	17.4	114
194	Purine synthesis promotes maintenance of brain tumor initiating cells in glioma. <i>Nature Neuroscience</i> , 2017 , 20, 661-673	25.5	93

193	Deubiquitinase USP13 maintains glioblastoma stem cells by antagonizing FBXL14-mediated Myc ubiquitination. <i>Journal of Experimental Medicine</i> , 2017 , 214, 245-267	16.6	78
192	Adaptive Chromatin Remodeling Drives Glioblastoma Stem Cell Plasticity and Drug Tolerance. <i>Cell Stem Cell</i> , 2017 , 20, 233-246.e7	18	235
191	Targeting Glioma Stem Cell-Derived Pericytes Disrupts the Blood-Tumor Barrier and Improves Chemotherapeutic Efficacy. <i>Cell Stem Cell</i> , 2017 , 21, 591-603.e4	18	105
190	Targeting glioma stem cells through combined BMI1 and EZH2 inhibition. <i>Nature Medicine</i> , 2017 , 23, 1352-1361	50.5	190
189	The p38 signaling pathway mediates quiescence of glioma stem cells by regulating epidermal growth factor receptor trafficking. <i>Oncotarget</i> , 2017 , 8, 33316-33328	3.3	13
188	EXTH-75. IMAGING GLIOBLASTOMA STEM CELLS WITH 7-AMINO ACID-LENGTH TUMOR-HOMING PEPTIDE IDENTIFIED BY PHAGE DISPLAY BIOPANNING. <i>Neuro-Oncology</i> , 2017 , 19, vi89-vi89	1	78
187	Zika virus has oncolytic activity against glioblastoma stem cells. <i>Journal of Experimental Medicine</i> , 2017 , 214, 2843-2857	16.6	109
186	New Advances and Challenges of Targeting Cancer Stem Cells. <i>Cancer Research</i> , 2017 , 77, 5222-5227	10.1	19
185	MYC-Regulated Mevalonate Metabolism Maintains Brain Tumor-Initiating Cells. <i>Cancer Research</i> , 2017 , 77, 4947-4960	10.1	65
184	Transcription elongation factors represent in vivo cancer dependencies in glioblastoma. <i>Nature</i> , 2017 , 547, 355-359	50.4	109
183	Tetraspanin CD9 stabilizes gp130 by preventing its ubiquitin-dependent lysosomal degradation to promote STAT3 activation in glioma stem cells. <i>Cell Death and Differentiation</i> , 2017 , 24, 167-180	12.7	42
182	GENE-32. ACTIVE CHROMATIN REGULATORY MAPS IDENTIFY CORE CELL STATE DRIVERS OF GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2017 , 19, vi99-vi99	1	78
181	SCDT-23. VISUALIZATION OF BRAIN TUMOR BY NEAR-INFRARED FLUORESCENCE IMAGING VIA TUMOR-TARGETING NOVEL PEPTIDE IDENTIFIED BY PHAGE DISPLAY. <i>Neuro-Oncology</i> , 2017 , 19, vi269-vi269	1	78
180	Constitutive Ras signaling and inactivation cooperate during the development of B-ALL in mice. <i>Blood Advances</i> , 2017 , 1, 2361-2374	7.8	9
179	Nicotinamide metabolism regulates glioblastoma stem cell maintenance. <i>JCI Insight</i> , 2017 , 2,	9.9	51
178	Transferrin receptor-1 and ferritin heavy and light chains in astrocytic brain tumors: Expression and prognostic value. <i>PLoS ONE</i> , 2017 , 12, e0182954	3.7	36
177	Cancer stem cells: master gatekeepers and regulators of cancer growth and metastasis Introduction. <i>Medicine (United States)</i> , 2016 , 95, S1	1.8	73
176	Chromosomal Instability Affects the Tumorigenicity of Glioblastoma Tumor-Initiating Cells. <i>Cancer Discovery</i> , 2016 , 6, 532-45	24.4	38

175	A Three-Dimensional Organoid Culture System Derived from Human Glioblastomas Recapitulates the Hypoxic Gradients and Cancer Stem Cell Heterogeneity of Tumors Found In Vivo. <i>Cancer Research</i> , 2016 , 76, 2465-77	10.1	291
174	Pharmacological Targeting of the Histone Chaperone Complex FACT Preferentially Eliminates Glioblastoma Stem Cells and Prolongs Survival in Preclinical Models. <i>Cancer Research</i> , 2016 , 76, 2432-42	10.1	45
173	An epigenetic gateway to brain tumor cell identity. <i>Nature Neuroscience</i> , 2016 , 19, 10-9	25.5	65
172	Coordination of self-renewal in glioblastoma by integration of adhesion and microRNA signaling. <i>Neuro-Oncology</i> , 2016 , 18, 656-66	1	26
171	RBPJ maintains brain tumor-initiating cells through CDK9-mediated transcriptional elongation. <i>Journal of Clinical Investigation</i> , 2016 , 126, 2757-72	15.9	35
170	Direct contact with perivascular tumor cells enhances integrin $\alpha 3$ signaling and migration of endothelial cells. <i>Oncotarget</i> , 2016 , 7, 43852-43867	3.3	18
169	Cancer Stem Cell-Secreted Macrophage Migration Inhibitory Factor Stimulates Myeloid Derived Suppressor Cell Function and Facilitates Glioblastoma Immune Evasion. <i>Stem Cells</i> , 2016 , 34, 2026-39	5.8	133
168	Cancer stem cells: understanding tumor hierarchy and heterogeneity. <i>Medicine (United States)</i> , 2016 , 95, S2-S7	1.8	118
167	The ID1-CULLIN3 Axis Regulates Intracellular SHH and WNT Signaling in Glioblastoma Stem Cells. <i>Cell Reports</i> , 2016 , 16, 1629-1641	10.6	32
166	Hyperthermia Sensitizes Glioma Stem-like Cells to Radiation by Inhibiting AKT Signaling. <i>Cancer Research</i> , 2015 , 75, 1760-9	10.1	58
165	Development of a Sox2 reporter system modeling cellular heterogeneity in glioma. <i>Neuro-Oncology</i> , 2015 , 17, 361-71	1	18
164	Cancer stem cells in glioblastoma. <i>Genes and Development</i> , 2015 , 29, 1203-17	12.6	851
163	Differential connexin function enhances self-renewal in glioblastoma. <i>Cell Reports</i> , 2015 , 11, 1031-42	10.6	80
162	Mitochondrial control by DRP1 in brain tumor initiating cells. <i>Nature Neuroscience</i> , 2015 , 18, 501-10	25.5	222
161	Feedback circuitry between miR-218 repression and RTK activation in glioblastoma. <i>Science Signaling</i> , 2015 , 8, ra42	8.8	11
160	Development of a Fluorescent Reporter System to Delineate Cancer Stem Cells in Triple-Negative Breast Cancer. <i>Stem Cells</i> , 2015 , 33, 2114-2125	5.8	53
159	The mitotic kinesin KIF11 is a driver of invasion, proliferation, and self-renewal in glioblastoma. <i>Science Translational Medicine</i> , 2015 , 7, 304ra143	17.5	90
158	"PEAR-ing" Genomic and Epigenomic Analyses for Cancer Gene Discovery. <i>Cancer Discovery</i> , 2015 , 5, 1018-20	24.4	1

157	Growth Factor Receptor Fusions Predict Therapeutic Sensitivity. <i>Clinical Cancer Research</i> , 2015 , 21, 3105-12.	17.9	
156	Preferential Iron Trafficking Characterizes Glioblastoma Stem-like Cells. <i>Cancer Cell</i> , 2015 , 28, 441-455	24.3	160
155	Lending an OLPing hand to tumor initiation. <i>Journal of Experimental Medicine</i> , 2015 , 212, 1989	16.6	
154	MLL5 Orchestrates a Cancer Self-Renewal State by Repressing the Histone Variant H3.3 and Globally Reorganizing Chromatin. <i>Cancer Cell</i> , 2015 , 28, 715-729	24.3	64
153	Arsenic trioxide disrupts glioma stem cells via promoting PML degradation to inhibit tumor growth. <i>Oncotarget</i> , 2015 , 6, 37300-15	3.3	33
152	CBIO-15NON-METABOLIC FUNCTION OF PHOSPHOFRUCTOKINASE-1 IN GLIOBLASTOMA MAINTENANCE. <i>Neuro-Oncology</i> , 2015 , 17, v58.1-v58	1	78
151	ZNF555 protein binds to transcriptional activator site of 4qA allele and ANT1: potential implication in Facioscapulohumeral dystrophy. <i>Nucleic Acids Research</i> , 2015 , 43, 8227-42	20.1	4
150	Cancer stem cells: targeting the roots of cancer, seeds of metastasis, and sources of therapy resistance. <i>Cancer Research</i> , 2015 , 75, 924-9	10.1	169
149	Periostin secreted by glioblastoma stem cells recruits M2 tumour-associated macrophages and promotes malignant growth. <i>Nature Cell Biology</i> , 2015 , 17, 170-82	23.4	490
148	CDC20 maintains tumor initiating cells. <i>Oncotarget</i> , 2015 , 6, 13241-54	3.3	35
147	Cancer stem cell-specific scavenger receptor CD36 drives glioblastoma progression. <i>Stem Cells</i> , 2014 , 32, 1746-58	5.8	127
146	The zinc finger transcription factor ZFX is required for maintaining the tumorigenic potential of glioblastoma stem cells. <i>Stem Cells</i> , 2014 , 32, 2033-47	5.8	33
145	miR-218 opposes a critical RTK-HIF pathway in mesenchymal glioblastoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014 , 111, 291-6	11.5	87
144	Profilin-1 phosphorylation directs angiocrine expression and glioblastoma progression through HIF-1 α accumulation. <i>Nature Cell Biology</i> , 2014 , 16, 445-56	23.4	61
143	High-Speed Coherent Raman Fingerprint Imaging of Biological Tissues. <i>Nature Photonics</i> , 2014 , 8, 627-634.	35.9	260
142	The tailless root of glioma: cancer stem cells. <i>Cell Stem Cell</i> , 2014 , 15, 114-6	18	12
141	Molecular targeting of TRF2 suppresses the growth and tumorigenesis of glioblastoma stem cells. <i>Glia</i> , 2014 , 62, 1687-98	9	27
140	Glioma cancer stem cells secrete Gremlin1 to promote their maintenance within the tumor hierarchy. <i>Genes and Development</i> , 2014 , 28, 1085-100	12.6	98

139	The Lgr5 transgene is expressed specifically in glycinergic amacrine cells in the mouse retina. <i>Experimental Eye Research</i> , 2014 , 119, 106-10	3.7	18
138	High-throughput flow cytometry screening reveals a role for junctional adhesion molecule a as a cancer stem cell maintenance factor. <i>Cell Reports</i> , 2014 , 6, 117-29	10.6	61
137	SC-32 * TARGETING PROLIFERATION AND INVASION IN GLIOBLASTOMA VIA MITOTIC KINESINS. <i>Neuro-Oncology</i> , 2014 , 16, v203-v204	1	78
136	Lgr5 Marks Post-Mitotic, Lineage Restricted Cerebellar Granule Neurons during Postnatal Development. <i>PLoS ONE</i> , 2014 , 9, e114433	3.7	10
135	Sema3C promotes the survival and tumorigenicity of glioma stem cells through Rac1 activation. <i>Cell Reports</i> , 2014 , 9, 1812-1826	10.6	79
134	SC-13ID1-CULLIN3 AXIS REGULATES STEM CELL SIGNALING IN GLIOMA. <i>Neuro-Oncology</i> , 2014 , 16, v199-v199	78	
133	Role of cysteine-rich 61 protein (CCN1) in macrophage-mediated oncolytic herpes simplex virus clearance. <i>Molecular Therapy</i> , 2014 , 22, 1678-87	11.7	32
132	Brain tumor stem cells: Molecular characteristics and their impact on therapy. <i>Molecular Aspects of Medicine</i> , 2014 , 39, 82-101	16.7	120
131	Lineage-specific splicing of a brain-enriched alternative exon promotes glioblastoma progression. <i>Journal of Clinical Investigation</i> , 2014 , 124, 2861-76	15.9	58
130	Brain tumor initiating cells adapt to restricted nutrition through preferential glucose uptake. <i>Nature Neuroscience</i> , 2013 , 16, 1373-82	25.5	306
129	Aptamer identification of brain tumor-initiating cells. <i>Cancer Research</i> , 2013 , 73, 4923-36	10.1	50
128	Mitotic control of cancer stem cells. <i>Cancer Discovery</i> , 2013 , 3, 141-4	24.4	7
127	Tumor cells upregulate normoxic HIF-1 α in response to doxorubicin. <i>Cancer Research</i> , 2013 , 73, 6230-42	10.1	83
126	Multiplex flow cytometry barcoding and antibody arrays identify surface antigen profiles of primary and metastatic colon cancer cell lines. <i>PLoS ONE</i> , 2013 , 8, e53015	3.7	24
125	Glioblastoma stem cells generate vascular pericytes to support vessel function and tumor growth. <i>Cell</i> , 2013 , 153, 139-52	56.2	572
124	Growth factor receptors define cancer hierarchies. <i>Cancer Cell</i> , 2013 , 23, 135-7	24.3	6
123	Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells. <i>Cancer Cell</i> , 2013 , 23, 839-52	24.3	506
122	Decoding the cancer stem cell hypothesis in glioblastoma. <i>CNS Oncology</i> , 2013 , 2, 319-30	4	20

121	Chemotherapy activates cancer-associated fibroblasts to maintain colorectal cancer-initiating cells by IL-17A. <i>Journal of Experimental Medicine</i> , 2013 , 210, 2851-72	16.6	223
120	ECatenin/POU5F1/SOX2 transcription factor complex mediates IGF-I receptor signaling and predicts poor prognosis in lung adenocarcinoma. <i>Cancer Research</i> , 2013 , 73, 3181-9	10.1	71
119	The evolving landscape of glioblastoma stem cells. <i>Current Opinion in Neurology</i> , 2013 , 26, 701-7	7.1	61
118	Leptin receptor maintains cancer stem-like properties in triple negative breast cancer cells. <i>Endocrine-Related Cancer</i> , 2013 , 20, 797-808	5.7	75
117	Changing the fate of cancer, one splice at a time. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013 , 110, 14510-1	11.5	1
116	Lyn facilitates glioblastoma cell survival under conditions of nutrient deprivation by promoting autophagy. <i>PLoS ONE</i> , 2013 , 8, e70804	3.7	21
115	Cadherin-11 regulates motility in normal cortical neural precursors and glioblastoma. <i>PLoS ONE</i> , 2013 , 8, e70962	3.7	23
114	Pharmacokinetic drug interaction between AEE788 and RAD001 causing thrombocytopenia in patients with glioblastoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2012 , 69, 281-7	3.5	11
113	Outcome after bevacizumab clinical trial therapy among recurrent grade III malignant glioma patients. <i>Journal of Neuro-Oncology</i> , 2012 , 107, 213-21	4.8	21
112	Laminin alpha 2 enables glioblastoma stem cell growth. <i>Annals of Neurology</i> , 2012 , 72, 766-78	9.4	117
111	Autocrine VEGF-VEGFR2-Neuropilin-1 signaling promotes glioma stem-like cell viability and tumor growth. <i>Journal of Experimental Medicine</i> , 2012 , 209, 507-20	16.6	290
110	The quest for self-identity: not all cancer stem cells are the same. <i>Clinical Cancer Research</i> , 2012 , 18, 3495-39	5.89	12
109	Chemokine CXCL12 in neurodegenerative diseases: an SOS signal for stem cell-based repair. <i>Trends in Neurosciences</i> , 2012 , 35, 619-28	13.3	72
108	Synthesis and preliminary evaluation of n.c.a. iodoquinone: a novel radiotracer with high uptake in cells with high ALDH1 expression. <i>Current Radiopharmaceuticals</i> , 2012 , 5, 47-58	1.8	
107	Holding on to stemness. <i>Nature Cell Biology</i> , 2012 , 14, 450-2	23.4	4
106	Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma. <i>Cancer</i> , 2012 , 118, 4759-67	6.4	26
105	Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma. <i>Journal of Neuro-Oncology</i> , 2012 , 108, 499-506	4.8	36
104	Molecularly targeted therapy in neuro-oncology. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2012 , 104, 255-78	3	8

103	Endothelial expression of TNF receptor-1 generates a proapoptotic signal inhibited by integrin $\beta 1$ in glioblastoma. <i>Cancer Research</i> , 2012 , 72, 1428-37	10.1	30
102	MET signaling regulates glioblastoma stem cells. <i>Cancer Research</i> , 2012 , 72, 3828-38	10.1	130
101	Platelet-derived growth factor receptors differentially inform intertumoral and intratumoral heterogeneity. <i>Genes and Development</i> , 2012 , 26, 1247-62	12.6	75
100	Looking in the miR-ror: TGF- β -mediated activation of NF- κ B in glioma. <i>Journal of Clinical Investigation</i> , 2012 , 122, 3473-5	15.9	6
99	Glioma stem cell proliferation and tumor growth are promoted by nitric oxide synthase-2. <i>Cell</i> , 2011 , 146, 53-66	56.2	240
98	Glioma development: where did it all go wrong?. <i>Cell</i> , 2011 , 146, 187-8	56.2	18
97	Elevated invasive potential of glioblastoma stem cells. <i>Biochemical and Biophysical Research Communications</i> , 2011 , 406, 643-8	3.4	135
96	Deadly teamwork: neural cancer stem cells and the tumor microenvironment. <i>Cell Stem Cell</i> , 2011 , 8, 482-5	18	182
95	HIF induces human embryonic stem cell markers in cancer cells. <i>Cancer Research</i> , 2011 , 71, 4640-52	10.1	390
94	Direct in vivo evidence for tumor propagation by glioblastoma cancer stem cells. <i>PLoS ONE</i> , 2011 , 6, e24867	3.7	99
93	Bacterial flavohemoglobin: a molecular tool to probe mammalian nitric oxide biology. <i>BioTechniques</i> , 2011 , 50, 41-5	2.5	15
92	Glioma stem cell maintenance: the role of the microenvironment. <i>Current Pharmaceutical Design</i> , 2011 , 17, 2386-401	3.3	67
91	Deubiquitylase HAUSP stabilizes REST and promotes maintenance of neural progenitor cells. <i>Nature Cell Biology</i> , 2011 , 13, 142-52	23.4	118
90	L1CAM regulates DNA damage checkpoint response of glioblastoma stem cells through NBS1. <i>EMBO Journal</i> , 2011 , 30, 800-13	13	127
89	Nonreceptor tyrosine kinase BMX maintains self-renewal and tumorigenic potential of glioblastoma stem cells by activating STAT3. <i>Cancer Cell</i> , 2011 , 19, 498-511	24.3	200
88	Twisted tango: brain tumor neurovascular interactions. <i>Nature Neuroscience</i> , 2011 , 14, 1375-81	25.5	59
87	Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. <i>Journal of Neuro-Oncology</i> , 2011 , 103, 371-9	4.8	72
86	Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma. <i>Journal of Neuro-Oncology</i> , 2011 , 105, 621-7	4.8	51

85	Seeing is believing: are cancer stem cells the Loch Ness monster of tumor biology?. <i>Stem Cell Reviews and Reports</i> , 2011 , 7, 227-37	6.4	26
84	Cancer stem cells in gliomas: identifying and understanding the apex cell in cancer hierarchy. <i>Glia</i> , 2011 , 59, 1148-54	9	110
83	Using a stem cell-based signature to guide therapeutic selection in cancer. <i>Cancer Research</i> , 2011 , 71, 1772-80	10.1	91
82	Leptin deficiency suppresses MMTV-Wnt-1 mammary tumor growth in obese mice and abrogates tumor initiating cell survival. <i>Endocrine-Related Cancer</i> , 2011 , 18, 491-503	5.7	96
81	Molecular targeting of neural cancer stem cells: TTAGGG, you're it!. <i>Clinical Cancer Research</i> , 2011 , 17, 3-5	12.9	3
80	Dynamic and transient cancer stem cells nurture melanoma. <i>Nature Medicine</i> , 2010 , 16, 758	50.5	9
79	Receptor channel TRPC6 is a key mediator of Notch-driven glioblastoma growth and invasiveness. <i>Cancer Research</i> , 2010 , 70, 418-27	10.1	143
78	Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma. <i>Neuro-Oncology</i> , 2010 , 12, 1300-10	1	171
77	Targeting A20 decreases glioma stem cell survival and tumor growth. <i>PLoS Biology</i> , 2010 , 8, e1000319	9.7	103
76	Erythropoietin Receptor Signaling Through STAT3 Is Required For Glioma Stem Cell Maintenance. <i>Genes and Cancer</i> , 2010 , 1, 50-61	2.9	60
75	Improving the radiosensitivity of radioresistant and hypoxic glioblastoma. <i>Future Oncology</i> , 2010 , 6, 1591-601	3.601	42
74	Integrin alpha 6 regulates glioblastoma stem cells. <i>Cell Stem Cell</i> , 2010 , 6, 421-32	18	484
73	Notch promotes radioresistance of glioma stem cells. <i>Stem Cells</i> , 2010 , 28, 17-28	5.8	415
72	Blood vessels in neurological development and disease: more than silent spectators. <i>Future Neurology</i> , 2010 , 5, 779-781	1.5	
71	Potential therapeutic implications of cancer stem cells in glioblastoma. <i>Biochemical Pharmacology</i> , 2010 , 80, 654-65	6	159
70	Heterologous expression of microbial flavohemoglobin can modulate the effects of nitric oxide in mammalian cells. <i>FASEB Journal</i> , 2010 , 24, 871.2	0.9	
69	The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype. <i>Cell Cycle</i> , 2009 , 8, 3274-84	4.7	613
68	NDRG4 is required for cell cycle progression and survival in glioblastoma cells. <i>Journal of Biological Chemistry</i> , 2009 , 284, 25160-9	5.4	44

67	Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma. <i>Journal of Clinical Oncology</i> , 2009 , 27, 1262-7	2.2	226
66	Phase II trial of Gliadel plus O6-benzylguanine in adults with recurrent glioblastoma multiforme. <i>Clinical Cancer Research</i> , 2009 , 15, 1064-8	12.9	50
65	Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma. <i>Neuro-Oncology</i> , 2009 , 11, 556-61	1	26
64	Turning cancer stem cells inside out: an exploration of glioma stem cell signaling pathways. <i>Journal of Biological Chemistry</i> , 2009 , 284, 16705-16709	5.4	76
63	Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. <i>Cancer Cell</i> , 2009 , 15, 501-11.3	11.3	1005
62	Biology of glioma cancer stem cells. <i>Molecules and Cells</i> , 2009 , 28, 7-12	3.5	106
61	Targeting interleukin 6 signaling suppresses glioma stem cell survival and tumor growth. <i>Stem Cells</i> , 2009 , 27, 2393-404	5.8	250
60	Squelching glioblastoma stem cells by targeting REST for proteasomal degradation. <i>Trends in Neurosciences</i> , 2009 , 32, 559-65	13.3	26
59	Efficacy of high-dose chemotherapy or standard salvage therapy in patients with recurrent medulloblastoma. <i>Neuro-Oncology</i> , 2008 , 10, 745-51	1	50
58	Designer therapies for glioblastoma multiforme. <i>Annals of the New York Academy of Sciences</i> , 2008 , 1142, 108-32	6.5	83
57	Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma. <i>Neuro-Oncology</i> , 2008 , 10, 330-40	1	35
56	Targeting cancer stem cells through L1CAM suppresses glioma growth. <i>Cancer Research</i> , 2008 , 68, 6043-80.1	80.1	312
55	Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas. <i>Clinical Cancer Research</i> , 2008 , 14, 7068-73	12.9	152
54	A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost. <i>Neuro-Oncology</i> , 2008 , 10, 182-9	1	79
53	c-Myc is required for maintenance of glioma cancer stem cells. <i>PLoS ONE</i> , 2008 , 3, e3769	3.7	295
52	Brain cancer stem cells display preferential sensitivity to Akt inhibition. <i>Stem Cells</i> , 2008 , 26, 3027-36	5.8	180
51	Diagnosis and treatment of high-grade astrocytoma. <i>Neurologic Clinics</i> , 2007 , 25, 1111-39, x	4.5	74
50	Molecularly targeted therapy for malignant glioma. <i>Cancer</i> , 2007 , 110, 13-24	6.4	245

49	Making a tumour bed: glioblastoma stem cells and the vascular niche. <i>Nature Reviews Cancer</i> , 2007 , 7, 733-6	31.3	558
48	Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas. <i>Journal of Neuro-Oncology</i> , 2007 , 83, 53-60	4.8	87
47	Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. <i>Journal of Clinical Oncology</i> , 2007 , 25, 4722-9	2.2	1119
46	Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. <i>Clinical Cancer Research</i> , 2007 , 13, 1253-9	12.9	896
45	Malignant glioma drug discovery - targeting protein kinases. <i>Expert Opinion on Drug Discovery</i> , 2007 , 2, 1-17	6.2	18
44	Antiangiogenic therapy in malignant glioma: promise and challenge. <i>Current Pharmaceutical Design</i> , 2007 , 13, 3545-58	3.3	36
43	Phase II study of Cloretazine for the treatment of adults with recurrent glioblastoma multiforme. <i>Neuro-Oncology</i> , 2007 , 9, 70-4	1	13
42	The combination of novel low molecular weight inhibitors of RAF (LBT613) and target of rapamycin (RAD001) decreases glioma proliferation and invasion. <i>Molecular Cancer Therapeutics</i> , 2007 , 6, 2449-57	6.1	38
41	Chemotherapy and cancer stem cells. <i>Cell Stem Cell</i> , 2007 , 1, 353-5	18	115
40	Cancer stem cells in radiation resistance. <i>Cancer Research</i> , 2007 , 67, 8980-4	10.1	389
39	Second messenger systems in human gliomas. <i>Archives of Pathology and Laboratory Medicine</i> , 2007 , 131, 1585-90	5	30
38	Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results. <i>Journal of Clinical Oncology</i> , 2006 , 24, 115-22	2.2	165
37	Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma. <i>Clinical Cancer Research</i> , 2006 , 12, 860-8	12.9	173
36	New treatment strategies for malignant gliomas. <i>Expert Review of Anticancer Therapy</i> , 2006 , 6, 1087-1043,5	3.5	108
35	Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. <i>Cancer Research</i> , 2006 , 66, 7843-8	10.1	1069
34	APOE4-VLDL inhibits the HDL-activated phosphatidylinositol 3-kinase/Akt Pathway via the phosphoinositol phosphatase SHIP2. <i>Circulation Research</i> , 2006 , 99, 829-36	15.7	19
33	AAL881, a novel small molecule inhibitor of RAF and vascular endothelial growth factor receptor activities, blocks the growth of malignant glioma. <i>Cancer Research</i> , 2006 , 66, 8722-30	10.1	47
32	Recent advances in the treatment of malignant astrocytoma. <i>Journal of Clinical Oncology</i> , 2006 , 24, 1253-65	3.65	258

31	New approaches to primary brain tumor treatment. <i>Anti-Cancer Drugs</i> , 2006 , 17, 1003-16	2.4	36
30	Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. <i>Nature</i> , 2006 , 444, 756-60	50.4	4706
29	Novel human IgG2b/murine chimeric antitenascin monoclonal antibody construct radiolabeled with 131I and administered into the surgically created resection cavity of patients with malignant glioma: phase I trial results. <i>Journal of Nuclear Medicine</i> , 2006 , 47, 912-8	8.9	32
28	Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. <i>Journal of Clinical Oncology</i> , 2005 , 23, 9359-68	2.2	286
27	Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma. <i>Cancer</i> , 2005 , 103, 329-38	6.4	110
26	Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma. <i>Cancer</i> , 2005 , 104, 1478-86	6.4	73
25	ZD6474, a novel tyrosine kinase inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor, inhibits tumor growth of multiple nervous system tumors. <i>Clinical Cancer Research</i> , 2005 , 11, 8145-57	12.9	91
24	Loss of phosphatase and tensin homologue increases transforming growth factor beta-mediated invasion with enhanced SMAD3 transcriptional activity. <i>Cancer Research</i> , 2005 , 65, 11276-81	10.1	36
23	Gene expression profiling and genetic markers in glioblastoma survival. <i>Cancer Research</i> , 2005 , 65, 4051-80.1	80.1	263
22	Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. <i>Molecular Cancer Therapeutics</i> , 2005 , 4, 101-12	6.1	169
21	Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme. <i>Clinical Cancer Research</i> , 2004 , 10, 3216-24	12.9	137
20	Phase II trial of gefitinib in recurrent glioblastoma. <i>Journal of Clinical Oncology</i> , 2004 , 22, 133-42	2.2	607
19	Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma. <i>Neuro-Oncology</i> , 2004 , 6, 145-53	1	19
18	Secreted protein acidic, rich in cysteine (SPARC), mediates cellular survival of gliomas through AKT activation. <i>Journal of Biological Chemistry</i> , 2004 , 279, 52200-9	5.4	92
17	Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma. <i>Neuro-Oncology</i> , 2004 , 6, 134-44	1	32
16	Development of novel targeted therapies in the treatment of malignant glioma. <i>Nature Reviews Drug Discovery</i> , 2004 , 3, 430-46	64.1	187
15	Periostin potently promotes metastatic growth of colon cancer by augmenting cell survival via the Akt/PKB pathway. <i>Cancer Cell</i> , 2004 , 5, 329-39	24.3	429
14	SB-431542, a small molecule transforming growth factor-beta-receptor antagonist, inhibits human glioma cell line proliferation and motility. <i>Molecular Cancer Therapeutics</i> , 2004 , 3, 737-45	6.1	149

13	Phase II trial of temozolomide in patients with progressive low-grade glioma. <i>Journal of Clinical Oncology</i> , 2003 , 21, 646-51	2.2	218
12	Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors. <i>Journal of Neuro-Oncology</i> , 2003 , 65, 27-35	4.8	198
11	Bone-related genes expressed in advanced malignancies induce invasion and metastasis in a genetically defined human cancer model. <i>Journal of Biological Chemistry</i> , 2003 , 278, 15951-7	5.4	121
10	High-dose chemotherapy with autologous stem-cell rescue in children and adults with newly diagnosed pineoblastomas. <i>Journal of Clinical Oncology</i> , 2003 , 21, 2187-91	2.2	90
9	Phase II trial of murine (131I)-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. <i>Journal of Clinical Oncology</i> , 2002 , 20, 1389-97	2.2	206
8	Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma. <i>Journal of Clinical Oncology</i> , 2002 , 20, 2277-83	2.2	156
7	Distinct requirements for Ras oncogenesis in human versus mouse cells. <i>Genes and Development</i> , 2002 , 16, 2045-57	12.6	340
6	Transforming growth factor-beta signaling in cancer. <i>Microscopy Research and Technique</i> , 2001 , 52, 363-738		43
5	Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. <i>Journal of Clinical Oncology</i> , 2000 , 18, 3522-8	2.2	111
4	Irinotecan therapy in adults with recurrent or progressive malignant glioma. <i>Journal of Clinical Oncology</i> , 1999 , 17, 1516-25	2.2	303
3	Transforming growth factor-beta-mediated p15(INK4B) induction and growth inhibition in astrocytes is SMAD3-dependent and a pathway prominently altered in human glioma cell lines. <i>Journal of Biological Chemistry</i> , 1999 , 274, 35053-8	5.4	90
2	Meningioma epigenetic grouping reveals biologic drivers and therapeutic vulnerabilities		2
1	PI3K inhibition suppresses microglia/TAM accumulation in glioblastoma microenvironment to promote exceptional temozolomide response		3